Concino owns full rights to the production and commercialization of Ad5-nCoV

June 8, Concino Bio issued a clarification announcement, noting the company's stock price fluctuations and some media reports about the restructuring of the new coronavirus vaccine (Ad5-nCoV) produced in Guizhou. Ad5-nCoV is jointly developed and owned by the Company and the Institute of Bioengineering of the Institute of Military Medicine of the Academy of Military Sciences. The Company has full rights to the production and commercialization of Ad5-nCoV, and according to the Drug Administration Law of the People's Republic of China and the Vaccine Administration Law of the People's Republic of China, vaccine producers should have sufficient capacity and qualifications to produce vaccines and be regulated by the State Drug Administration.Ad5-nCoV is built using genetic engineering methods to replicate defective human type 5 adenovirus as a vector to express the new coronavirus S antigen, intended to be used to prevent diseases caused by new coronavirus infection.It was previously reported that the Lancet, an international authoritative medical journal, published clinical results of Ad5-nCoV's Phase I human trials online on May 22. The results showed that all 108 volunteers in phase I had significant cellular immune response. This is the world's first new crown vaccine human clinical data. Ad5-nCoV, as the first COVID-19 vaccine to enter phase I clinical trials, has demonstrated excellent safety and tolerance to produce an immune response against SARS-CoV-2 in the human body, and is now in Phase II clinical trials. (
Sina Pharmaceutical News
)